Akash Saggam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Akash Saggam has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Bhushan Patwardhan
School of Health Sciences, Savitribai Phule Pune University, Pune, India
2 shared publications Girish Tillu
Affiliation AYUSH-Center of Excellence, Center for Complementary and Integrative Health, Interdisciplinary School of Health Sciences, Savitribai Phule Pune University, Pune, India
2 shared publicationsSwapnil Borse
Affiliation AYUSH-Center of Excellence, Center for Complementary and Integrative Health, Interdisciplinary School of Health Sciences, Savitribai Phule Pune University, Pune, India
2 shared publications- Aboli Girme
Pharmanza Herbal Pvt. Ltd., Anand, 388430, Gujarat, India
1 shared publication Aniket Marathe
Affiliation Bioinformatics Centre, Savitribai Phule Pune University, Pune, India
1 shared publication- Girish Tillu
Ayush Centre of Excellence, Department of Health Sciences, Savitribai Phule Pune University, Pune, India
1 shared publication
Latest Publications
- Open Access
- 28 April 2024
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 331, 118261
Molecular mechanisms of Asparagus racemosus willd. and Withania somnifera (L.) Dunal as chemotherapeutic adjuvants for breast cancer treatment
- 28 April 2024
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 331, 118261
Open AccessMolecular mechanisms of Asparagus racemosus willd. and Withania somnifera (L.) Dunal as chemotherapeutic adjuvants for breast cancer treatment
- 18 January 2024
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 15 (1) , 100848
Conference report: Dhara - Vision Ayurveda 2047
- 18 January 2024
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 15 (1) , 100848
Conference report: Dhara - Vision Ayurveda 2047
- Open Access
- 11 June 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (6) , e0248479
Ayurveda botanicals in COVID-19 management: An in silico multi-target approach
The Coronavirus disease (COVID-19) caused by the virus SARS-CoV-2 has become a global pandemic in a very short time span. Currently, there is no specific treatment or vaccine to counter this highly contagious disease. There is an urgent need to find a specific cure for the disease and global efforts are directed at developing SARS-CoV-2 specific antivirals and immunomodulators. AyurvedicRasayanatherapy has been traditionally used in India for its immunomodulatory and adaptogenic effects, and more recently has been included as therapeutic adjuvant for several maladies. Amongst several others,Withania somnifera(Ashwagandha),Tinospora cordifolia(Guduchi) andAsparagus racemosus(Shatavari) play an important role inRasayanatherapy. The objective of this study was to explore the immunomodulatory and anti SARS-CoV2 potential of phytoconstituents from Ashwagandha, Guduchi and Shatavari using network pharmacology and docking. The plant extracts were prepared as per ayurvedic procedures and a total of 31 phytoconstituents were identified using UHPLC-PDA and mass spectrometry studies. To assess the immunomodulatory potential of these phytoconstituents anin-siliconetwork pharmacology model was constructed. The model predicts that the phytoconstituents possess the potential to modulate several targets in immune pathways potentially providing a protective role. To explore if these phytoconstituents also possess antiviral activity, docking was performed with the Spike protein, Main Protease and RNA dependent RNA polymerase of the virus. Interestingly, several phytoconstituents are predicted to possess good affinity for the three targets, suggesting their application for the termination of viral life cycle. Further, predictive tools indicate that there would not be adverse herb-drug pharmacokinetic-pharmacodynamic interactions with concomitantly administered drug therapy. We thus make a compelling case to evaluate the potential of theseRasayanabotanicals as therapeutic adjuvants in the management of COVID-19 following rigorous experimental validation.
- 11 June 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (6) , e0248479
Open AccessAyurveda botanicals in COVID-19 management: An in silico multi-target approach
The Coronavirus disease (COVID-19) caused by the virus SARS-CoV-2 has become a global pandemic in a very short time span. Currently, there is no specific treatment or vaccine to counter this highly contagious disease. There is an urgent need to find a specific cure for the disease and global efforts are directed at developing SARS-CoV-2 specific antivirals and immunomodulators. AyurvedicRasayanatherapy has been traditionally used in India for its immunomodulatory and adaptogenic effects, and more recently has been included as therapeutic adjuvant for several maladies. Amongst several others,Withania somnifera(Ashwagandha),Tinospora cordifolia(Guduchi) andAsparagus racemosus(Shatavari) play an important role inRasayanatherapy. The objective of this study was to explore the immunomodulatory and anti SARS-CoV2 potential of phytoconstituents from Ashwagandha, Guduchi and Shatavari using network pharmacology and docking. The plant extracts were prepared as per ayurvedic procedures and a total of 31 phytoconstituents were identified using UHPLC-PDA and mass spectrometry studies. To assess the immunomodulatory potential of these phytoconstituents anin-siliconetwork pharmacology model was constructed. The model predicts that the phytoconstituents possess the potential to modulate several targets in immune pathways potentially providing a protective role. To explore if these phytoconstituents also possess antiviral activity, docking was performed with the Spike protein, Main Protease and RNA dependent RNA polymerase of the virus. Interestingly, several phytoconstituents are predicted to possess good affinity for the three targets, suggesting their application for the termination of viral life cycle. Further, predictive tools indicate that there would not be adverse herb-drug pharmacokinetic-pharmacodynamic interactions with concomitantly administered drug therapy. We thus make a compelling case to evaluate the potential of theseRasayanabotanicals as therapeutic adjuvants in the management of COVID-19 following rigorous experimental validation.
- 1 June 2020
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 255, 112759
Withania somnifera (L.) Dunal: A potential therapeutic adjuvant in cancer
- 1 June 2020
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 255, 112759
Withania somnifera (L.) Dunal: A potential therapeutic adjuvant in cancer